Hackers slipped a trojan into the code library behind most of the internet. Your team is probably affected

Attackers stole a long-lived npm token from the lead axios maintainer and published two poisoned versions that drop a ...
Dark Reading

Axios NPM Package Compromised in Precision Attack

The NPM package for Axios, a popular JavaScript HTTP client library, was briefly compromised this week, possibly by North ...

What Is A Prediction Market?

Prediction markets allow consumers to trade event contracts tied to real-world outcomes, from elections to economic data and ...

A New U.S. Missile Hit a Sports Hall in Iran. Here’s What We Know About It.

Barely out of prototype testing, the Precision Strike Missile is shrouded in secrecy — including which Persian Gulf countries ...

What to Know About Zillow’s Major New Listings Feature

The massive real estate marketplace just changed its tune around pre-market listings, shifting the landscape for brokers and ...
CoinDesk

How a Solana feature designed for convenience let attackers drain more than $270 million from Drift

The exploit did not involve a bug in Drift's code. It used "durable nonces," a legitimate Solana transaction feature, to pre-sign administrative transfers weeks before executing them, bypassing the ...

We tried 3 of the biggest vibe-coding platforms. Here's what we thought about how they stack up.

Three app ideas, three platforms, three writers — ready, get set, code!
Seeking Alpha

PMN ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...
Seeking Alpha

PMN ProMIS Neurosciences, Inc.

Get the latest news and real-time alerts from ProMIS Neurosciences, Inc. (PMN) stock at Seeking Alpha.
Yahoo Finance

ProMIS Neurosciences, Inc. (PMN)

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 ...